Thursday, September 21, 2017
Company News: Page (1) of 1 - 03/17/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Acarix CADScorŪSystem Multi-center Trial Results Confirm Previous Preliminary Results Ruling out CAD With 97% Negative Predictive Value
  By PR Newswire

MALMO, Sweden, March 17, 2017 /PRNewswire/ --

Acarix AB (publ) ("Acarix") today announced the results from a new multi-center trial of its handheld CADScorŪSystem for non-invasive, non-radiation acoustic detection of Coronary Artery Disease ("CAD"). The results are presented at the American College of Cardiology 2017 Annual Scientific Meeting in Washington, 17-19 March 2017 and showed that the CADScorŪSystem rules out CAD with 97% negative predictive value. The results confirm previously announced figures by Acarix.

     (Photo: )

The CADScorŪSystem combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-score in less than 10 minutes. The research was led by Principal Investigator Morten Böttcher, MD PhD FESC and by Simon Winther, MD PhD, Department of Cardiology, Aarhus University Hospital, Denmark: "Despite the availability of improved risk stratification algorithms, the incidence of normal investigations such as nuclear or CT imaging remains high. We therefore tested the diagnostic accuracy of the CADScorŪSystem for ruling out CAD to see if it could be used to reduce demand for more advanced diagnostic modalities. We have concluded that, with its ability to rule out CAD with a 97% negative predictive value, this advanced, easy to use, stethoscope like device could indeed be deployed as a frontline test ."

A CAD-score was recorded in all 1,675 patients enrolled in the trial. Low risk was indicated by a CAD-score value ?20. Diagnostic performance evaluated by receiver operating characteristic curve showed an accuracy of: 72% (CI: 67% - 77%). CAD-score cut-off ?20 had an accuracy of:

? Sensitivity: 81% (CI: 74% to 88%)

? Specificity: 53% (CI: 50% to 56%)

? PPV: 15% (CI: 13% to 18%)

? NPV: 97% (CI:95% to 98%)

Acarix CEO Søren Rysholt Christiansen commented: "Coronary Artery Disease affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to expensive imaging and coronary angiography, is inefficient. A recent Danish study showed that more than 90% of patients presenting with chest pain symptoms to their general practitioner do not have CAD. If adopted, the CADScorŪSystem can provide rapid frontline assessment which could translate into a potential reduction in patient referrals by ~50%. - a win-win for patients, payers and physicians."

For a comprehensive press release, see

Acarix A/S
Søren Rysholt Christiansen, CEO
Phone: +45-2777-1112


Copyright 2014 PR Newswire. All Rights Reserved

Page: 1


About Digital Facility - Contact Us - Advertise With Us - Privacy Guidelines